Pentosan polysulfate - Paradigm Biopharma

Drug Profile

Pentosan polysulfate - Paradigm Biopharma

Alternative Names: Pentosan polysulfate sodium - Paradigm Biopharma; PPS - Paradigm Biopharma; Rhinosul; ZILOSUL

Latest Information Update: 25 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Glycan Biosciences; Griffith University
  • Developer Griffith University; Paradigm Biopharma
  • Class Analgesics; Anti-inflammatories; Anticoagulants; Antihyperlipidaemics; Antiretrovirals; Antithrombotics; Antivirals; Glycosaminoglycans; Polymers; Polysaccharides; Small molecules; Sulfuric acids
  • Mechanism of Action Cell membrane permeability inhibitors; Enzyme inhibitors; Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ross River virus infections; Seasonal allergic rhinitis
  • Phase I/II Oedema
  • Phase I Allergic rhinitis
  • Preclinical Allergic asthma; Chikungunya virus infections
  • Research Chronic obstructive pulmonary disease

Most Recent Events

  • 18 Sep 2017 Paradigm Biopharmaceuticals plans the PARA005 phase II trial for Pain in Australia (ACTRN12617001311347 )
  • 20 Jul 2017 Phase-II clinical trials in Ross River virus infections in Australia (SC) (ACTRN12617000893303)
  • 22 Jun 2017 Paradigm Biopharma plans a phase II trial for Ross River virus infections in Australia (ACTRN12617000893303)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top